Results 221 to 230 of about 117,142 (268)

Hypoxia, PAF, and Necrotizing Enterocolitis

Lipids, 1991
AbstractNecrotizing enterocolitis (NEC) is an important neonatal disease with a high mortality rate. The pathophysiology is unclear but epidemiologic studies suggest that hypoxia and infection are important risk factors. In this review we discuss the effect of hypoxia and platelet‐activating factor (PAF) on intestinal blood flow and intestinal necrosis,
M S, Caplan, X M, Sun, W, Hsueh
openaire   +2 more sources

Synthesis of a PAF Immunogen and Production of PAF-Specific Antibodies

Lipids, 1991
AbstractPlatelet activating factor (PAF), a naturally occurring phospholipid with many potent physiological and pharmacological activities, is implicated as a mediator of many diseases. An immunoassay for PAF would greatly improve quantitation, and hence PAF‐specific antibodies were required.
M A, Smal, B A, Baldo, J W, Redmond
openaire   +2 more sources

Paf‐acether in human skin

Lipids, 1991
AbstractPaf is a phospholipid mediator present in human skin which induces inflammatory events such as neutrophil infiltration and increased vascular permeability. Recent data suggest that cutaneous cells, such as fibroblasts and keratinocytes, produce paf and that paf is released during allergic cutaneous reactions.
Y, Denizot, L, Michel, J, Benveniste, A, Meybeck, Y, Thomas, L, Dubertret   +5 more
openaire   +2 more sources

PCA-4248, a PAF receptor antagonist, inhibits PAF-induced phosphoinositide turnover

European Journal of Pharmacology: Molecular Pharmacology, 1995
The effect of a new PAF (platelet activating factor; 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoryl-choline) receptor antagonist, PCA-4248 (2-phenylthio)ethyl-5-metoxycarbonyl-2,4,6-trimethyl-1, 4-dihydropyridine-3-carboxylate), on phosphoinositide turnover evoked by PAF was investigated.
R E, Catalán, A M, Martínez, M D, Aragonés, M, Lombardía, E, Garde   +4 more
openaire   +2 more sources

PAF

Drugs, 1991
Matyas Koltai, David Hosford, Philippe Guinot, André Esanu, Pierre Braquet   +4 more
openaire   +1 more source

Platelet Activating Factor (PAF): A Mediator of Inflammation

BioFactors, 2022
Julia E M Upton, Eyal Grunebaum, Peter Vadas   +2 more
exaly  

PAF

2006
  +4 more sources

Paf-acether (Platelet-activating Factor)

1986
Platelet-activating factor was first described as originating from IgE-sensitized rabbit basophils challenged with the specific allergen. When its structure, 1-O- alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine was unveiled in 1979, it was thus named “Paf-acether”, given the ether linkage at position 1 and the acetyl group at position 2 of glycerol. Paf-
openaire   +4 more sources

Platelet-activating factor (PAF) and PAF antagonists in asthma.

Critical reviews in therapeutic drug carrier systems, 1991
PAF is produced by and activates inflammatory cells, such as monocytes/macrophages, mast cells, platelets, neutrophils, eosinophils and endothelial cells. Its ability to imitate anaphylaxis, inducing for instance bronchoconstriction (BC) in guinea-pigs, and its identification (and/or that of lyso-PAF) in exudates from shocked lungs, led to the ...
D, Hosford, J M, Mencia-Huerta, P, Braquet   +2 more
openaire   +1 more source

Consumption of Enriched Yogurt with PAF Inhibitors from Olive Pomace Affects the Major Enzymes of PAF Metabolism: A Randomized, Double Blind, Three Arm Trial

Biomolecules, 2021
Maria Detopoulou, Filio Petsini, Elizabeth Fragopoulou   +2 more
exaly